Loading
A phase 3 trial testing Emactuzumab in tenosynovial giant cell tumour, active and no longer recruiting.
Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT) is a phase 3 interventional study registered as NCT05417789, led by SynOx Therapeutics, and active but no longer recruiting on the registry. Official title: A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour. Planned enrolment is 128 participants (estimated). The study started in 2024-10-09 and primary completion is expected in 2025-12-23. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/